Wearable ECG specialists acquire new testing facility to reach more patients

WearLinq, a San Francisco-based healthcare technology company, has acquired AMI Cardiac Monitoring, an independent diagnostic testing facility, to help increase the reach of its eWave six-lead wearable electrocardiogram (ECG) monitor. Financial details are not being shared at this time.

AMI has been delivering cardiac data to its customers for more than three decades. WearLinq sees the acquisition as a way to ensure patients in all 50 U.S. states can be treated with the eWave device, which works in tandem with a user’s smartphone to deliver long-term monitoring services. The eWave device can last up to five days on a single charge, according to WearLinq, and it sends automated alerts when the battery is low or signal quality suggests a new patch is required.

“The astute clinical capabilities of AMI combined with the advanced technology of WearLinq will create a tremendously productive partnership,” Konrad Morzkowski, WearLinq’s CEO, said in a prepared statement. “AMI and WearLinq share the same values and visions of providing excellent services for patients and clinical facilities. This synergy enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients and will undoubtedly position us as market leaders very soon.”